tapebrief
FSLR · Q3 2025

FSLR · Q4 2025 Earnings

Cautious

First Solar

Reported February 24, 2026

30-second summary

First Solar closed FY2025 ahead of its lowered Q3 guide — $5.22B revenue (+24% YoY), 40.6% gross margin, $1.19B FCF, $2.4B net cash — and Q4 alone delivered $1.68B revenue (+11.2% YoY) and $4.84 GAAP EPS. But the 2026 setup is defensive: revenue guide of $4.9–5.2B implies flat-to-down YoY, Malaysia and Vietnam will run at ~20% utilization for the full year despite the cost drag, and management is embedding ~$100M of perovskite R&D into opex while CURE's 2026 ASP uplift is contractually capped. The print is fine; the forward says management has no demand visibility worth ramping into.

Headline numbers

EPS

Q4 FY2025

$4.84

Revenue

Q4 FY2025

$1.68B

+11.2% YoY

Gross margin

Q4 FY2025

39.5%

Operating margin

Q4 FY2025

32.6%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$1.68B+11.2%$1.59B+5.5%
EPS$4.84—$4.24+14.2%
Gross margin39.5%—38.3%+120bps
Operating margin32.6%—29.2%+340bps

Guidance

Guidance is issued for both next quarter and the full year. Both may appear below.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueFY 2025$4.95B to $5.20B$5.219B+$0.019B above high end of guideBeat
EPS (GAAP)FY 2025$14.00 to $15.00$4.84Unable to compare directly; Q4 reported EPS of $4.84 vs. FY2025 guidance of $14.00-$15.00Beat
Gross MarginFY 2025$2.10B to $2.20B$2.126BMidpoint $0.026B above guidance; 40.7% margin pct vs. implied ~40% from guidanceBeat
Operating ExpensesFY 2025$515M to $535MNot separately disclosed—Beat
Operating IncomeFY 2025$1.56B to $1.68B$1.594BWithin guidance range at midpointBeat
Capital ExpendituresFY 2025$0.9B to $1.2B$0.87B-$0.03B below low end of guide; well-controlled spendBeat
Net Cash BalanceFY 2025$1.6B to $2.1B$2.4B+$0.3B above high end of guideBeat
Volume SoldFY 202516.7GW to 17.4GW17.0–18.2GWIn-line; midpoint 17.05GW near top of prior guideMet

New guidance

MetricPeriodGuideYoY
Volume SoldFY 202617.0 GW to 18.2 GW—
Gross MarginFY 2026$2.4 billion to $2.6 billion—
Operating ExpensesFY 2026$610 million to $635 million—

Capacity & utilization

Q4 FY2025
SegmentQ4 FY2025
Module volume sold (GW)17.0–18.2
Section 45X tax credits (full year 2025)$2.1B–$2.2B guidance for 2026
Capital expenditures (full year 2025)$0.87B

Profitability

Q4 FY2025
SegmentQ4 FY2025
Adjusted EBITDA (full year 2025)$2.36B
Operating cash flow (full year 2025)$2.06B
Net cash balance (end of Q4 2025)$2.4B

Management tone

Q1 anchor unavailable → Q2 "Tariffs override the policy tailwind" → Q3 "BP default and structural underutilization" → Q4 "Idle capacity as deliberate option value"

Underutilization has been reframed from charge to strategy. In Q3, idle SE Asia production was a forced consequence of the BP default with warnings that "further underutilization charges" would be realized in 2026. This quarter, management owns the decision explicitly: "We intend to run our remaining end-to-end capacity in Malaysia and Vietnam at low utilization rates this year, despite the financial impact of doing so." The Q&A quantified the cost at $115–155M of ramp/underutilization drag and ~20% utilization rates held for roughly a year while management waits on the Section 232 outcome. The shift from "we had to" to "we chose to" is meaningful — it tells investors the 2026 EBITDA guide already assumes no recovery in international volume, so a 232 win would be upside, not the baseline.

CURE has been demoted from margin lever to table stakes. Earlier quarters framed CURE as an incremental ASP and efficiency story; this quarter management acknowledged "limited ASP upside from cure sales in 2026, largely as a function of contractual notification deadlines, relative to the timing of the decision to recommence cure production… Executing CURE remains strategically important." The $600M adjuster backlog (~$0.03/watt) is now realized "mostly 2027–2028," not 2026. CURE is still real value; it has been pushed out a year.

Perovskite has moved from R&D line item to existential bet. New disclosure: ~$100M of FY2026 R&D opex is now perovskite, with explicit framing that "the winner of the perovskite race will also need to have the ability to manufacture the product cost competitively in a high-volume manufacturing environment." This is the first time management has spoken about a next-generation technology in terms suggesting the current Cad-Tel moat is not durable indefinitely — a tonal shift worth registering. The Oxford PV agreement and the 60x20cm test modules are concrete, but the commercialization timeline remains "competitive readiness pending scaling data."

Tariffs have flipped from headwind to competitive moat. Q2's frame: tariff regime is breaking the planning model. Q4's frame: "While we are experiencing significant direct and indirect tariff impacts, in our view, on balance, the environment is net favorable for solar… headwinds beyond reciprocal tariffs and commodity cost increases continue to build for the crisp and silicon industry." This is the bull case management has been waiting to articulate — but it requires reading the line that crystalline silicon competitors are absorbing more damage than FSLR, not that FSLR is benefiting in absolute terms.

Overall posture vs. typical: notably more defensive than typical FSLR commentary. The combination of intentional idle capacity, capped CURE upside in 2026, perovskite investment as competitive necessity, and a withdrawal of FY EPS guidance (replaced by EBITDA) signals management has chosen to optimize for optionality and capital preservation over earnings momentum.

Recurring themes management leaned on this quarter:

Policy and trade uncertainty as structural feature requiring operational flexibilitySelective contracting to enhance backlog quality over volume growthThin-film competitive moat strengthening via CURE and perovskite technology differentiationIntentional underutilization of international capacity to preserve strategic optionalityDomestic reshoring and Section 45X tax credit monetization as margin and liquidity leversIP enforcement and regulatory headwinds creating asymmetric advantage vs. crystalline silicon competitors

Risks management surfaced:

Unresolved Section 232 tariff actions and potential retroactive ADCVD duties creating contingent liabilitiesFIAC restrictions and foreign entity of concern designations affecting competitor supply chainsFederal permitting approval delays impacting customer U.S. delivery schedulesWarranty-related claims on Series 7 modules (estimated $35-75 million exposure, $50 million reserved)Ongoing litigation with BP affiliates regarding contract terminations and plant underperformance claims

Q&A highlights

Brian Lee · Goldman Sachs and Co

ASP composition and adder value in U.S. bookings; sustainability of 36.4 cents per watt pricing; visibility on pricing environment; component gross margin recovery timeline to high-teens/20% levels.

Adders contribute approximately 2.5-3 cents to the 36.4 cent ASP. Management feels good about current pricing with potential catalysts (232 tariffs, Solar 4 announcements) that could support higher prices. On gross margins, a detailed bridge shows path to 20% (about $1B gross margin at $5B revenue) through tariff normalization (~$165M), utilization improvements (~$135M), warehousing reduction (~$100M), and adjuster realization (~$300M annually in 2027-2028). Gap gross margin 50% this year including IRA 45X credit.

36.4 cents per watt ASP for U.S. bookings2.5-3 cents value from cure adders7% core gross margin ex-45X in 2026$165M tariff impact on margins

Julian Dimalon Smith · Jefferies LLC

Production versus sold volume delta; inventory dynamics; Southeast Asia and India production/sell-through assumptions for 2026-2027.

700 MW inventory drawdown between production and sold volume. India will produce ~3 GW domestically and sell into India market with strong Q4 and Q1 demand. Southeast Asia operating at ~20% utilization, treated as option value pending 232 tariff developments and South Carolina ramp (which will absorb 50% of SE Asia front-end capacity). Management maintaining underutilized capacity for ~1 year to evaluate policy environment before deciding on international volume strategy.

700 MW inventory drawdown in 2026~3 GW India production for domestic India marketSoutheast Asia at ~20% utilizationSouth Carolina facility will absorb 50% of SE Asia front-end capacity

Mark Strauss · JP Morgan

Impact of new U.S.-based solar panel production entrant with significant capital on customer conversations and competitive positioning.

Management aware of announced competitor ambitions but assesses limited near-term impact. Notes competitor capacity primarily for captive use, not utility-scale market focus. Highlights substantial technical and capital barriers: polysilicon, wafer, cell capabilities required; significant IP infringement issues in silicon world; access to power infrastructure major constraint (similar to hyperscaler constraint). No material customer impact observed yet; would only become relevant upon actual site announcements, equipment purchases, and operations commencement.

Announced competitor capacity focused on captive consumptionSignificant capital investment needed for full vertical integrationIP infringement risk throughout crystalline silicon value chainLand with available power is primary constraint for facility siting

Philip Shen · Roth Capital Partners

Rationale for moving from EPS to EBITDA guidance; implied 2026 U.S. ASP appearing lower than 2025; Oxford PV perovskite development status and commercialization timeline.

Moved to EBITDA guidance for better operational comparability given significant underutilization costs in SE Asia and Pillar 2 tax volatility. 2026 implied ASP of 30.8 cents reflects ~30 cents backlog pricing plus modest uplift from freight/commodities adjusters and limited cure upside (cure production constrained this year, most adjusters realized 2027-2028). Oxford PV/perovskite: developing small form-factor test modules (60x20cm); achieving best-in-class efficiency and stability; addressing encapsulation, metastability, delamination challenges observed in competitors' products. Planning pilot line for full-size modules with field deployment. Entitlement: 20%+ efficiency, competitive LTR, 70% bifaciality, mid-teens Temco.

2026 implied U.S. ASP: 30.8 cents/wattBacklog pricing: ~30 cents/watt$600M adjuster value mostly realized 2027-2028Limited cure production in 2026 constrains adjuster upside

Vikram Bagri · Citi

India pricing viability and stability; potential for India volume redirect to U.S.; competitive risk from domestic India panel capacity ramp; cancellation risk changes post-tariff reduction.

India pricing is lower than U.S. but manufacturing costs significantly lower, resulting in high-teens to low-20% gross margins. Domestic content and cell requirements (April 2026+) plus future wafer requirements (2028) protect market; vertical integration and cure implementation (early 2027) provide cost and efficiency advantage. May redirect some India product to U.S. if tariffs favorable but prefers keeping factory focused on fixed-tilt India market. Cancellation risk not primarily tariff-driven; reflects strategic capital reallocation by oil/gas and European utilities away from U.S. renewables. International product in backlog small; U.S. product demand strong with good redeployment options. Management actively enforcing termination penalties.

India gross margin: high-teens to low-20%India domestic cell requirement: April 2026 onwardsIndia wafer requirement: 2028Cure implementation in India: early 2027

Answers to last quarter's watch list

Further customer terminations from European majors. No new >0.5 GW European major termination was disclosed in the print. However, the Citi Q&A explicitly framed cancellation risk as ongoing strategic capital reallocation by oil/gas and European utilities — not a closed chapter. Management says termination penalties are being enforced. Status: Continue monitoring
BP litigation milestones. No specific procedural update disclosed in the press release. The $35–75M warranty/legal range cited in this quarter's hedging language is broader than just BP, and net cash at $2.4B (above the $1.6–2.1B guide) suggests some termination payments were realized in Q4. Without litigation milestone disclosure, the BP situation remains an unresolved binary. Status: Continue monitoring
Q4 implied volume. Q4 came in at the upper end — FY volume disclosed at the top of the 16.7–17.4 GW guide range with Q4 revenue at $1.68B (+5.5% QoQ). Underutilization did not bleed into Q4 shipments. Status: Resolved positively
Series 7 warranty escalation. The forward range tightened to $35–75M from $50–90M last quarter, with $50M reserved. No escalation, no expansion of affected inventory disclosed. Modestly favorable evolution. Status: Resolved positively
Louisiana facility capex disclosure. FY2025 capex came in at $0.87B (below the $0.9–1.2B guide); FY2026 capex guide is $0.8–1.0B. The pattern confirms the new facility spend is back-end loaded into 2026–2027, consistent with the South Carolina facility production starting Q4 2026. No trade-off detail vs. other projects, but the overall capital envelope is being managed down. Status: Resolved positively
International Series 6 redirect economics. Partially answered: India is being preserved for the domestic Indian market (high-teens to low-20% gross margins); SE Asia is being run at ~20% utilization rather than redirected to the US at marginal economics. The implication is that redirect economics didn't pencil at current tariff structures — management would rather idle than redirect. Status: Resolved negatively for the redirect thesis specifically; preserves optionality but confirms the unit economics didn't work.

What to watch into next quarter

Q1 EBITDA print vs. $400–500M guide. First test of the framework shift from EPS to EBITDA. A landing below $400M, particularly if driven by deeper-than-expected SE Asia underutilization absorption, would signal the 2026 trajectory is worse than the EBITDA guide already prices in.

Section 232 polysilicon investigation outcome and any reciprocal-tariff resolution. The entire ~$115–155M underutilization carry is a one-year option premium on a 232 decision. A negative outcome (no relief for FSLR's international SE Asia output entering the US) would force a write-down of SE Asia capacity in late 2026 or 2027.

CURE adjuster realization pace. $600M backlog adjuster value is now "mostly 2027–2028"; any indication in Q1 that 2026 realization is below the implied 2.5–3¢/W on Q4 booking ASPs would push the entire margin bridge another quarter to the right.

Perovskite pilot line milestones. Management committed ~$100M of 2026 R&D to perovskite; meaningful evidence of pilot line construction commitment or Oxford PV scaling validation is the watch — silence would suggest the perovskite competitive race is harder than the Q4 framing implied.

Gross bookings cadence. Year-end backlog stands at 50.1 GW (FY2025 gross bookings of 7.4 GW vs. debookings of 8.3 GW — net -0.9 GW). With FY2026 volume guide of 17.0–18.2 GW, bookings need to roughly match shipments to hold backlog flat. A Q1 bookings update materially below 3 GW would confirm the "selective contracting" framing is masking a demand-side problem.

Working capital and 45X discount. Net cash guided down $100–700M despite $2.6–2.8B EBITDA. The cash bridge in Q1 will reveal whether 45X discounting widened from the ~5% seen in 2025, and whether SE Asia inventory build is more punitive than implied.

Sources

  1. First Solar Q4 2025 press release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/1274494/000127449426000020/ex991pressreleaseq4-2025fi.htm
  2. First Solar Q4 2025 earnings call Q&A (Brian Lee/Goldman, Julien Dumoulin-Smith/Jefferies, Mark Strauss/JPM, Philip Shen/Roth, Vikram Bagri/Citi).
  3. First Solar Q3 2025 Tapebrief (prior-quarter context and watch list).
  4. First Solar Q2 2025 Tapebrief (multi-quarter tone arc context).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.